
The results of multicenter, randomized clinical trial show that a 7-day course of antibiotics for patients hospitalized with bloodstream infections is non-inferior to a 14- day course, researchers reported at IDWeek 2024.
The trial, conducted at 74 hospitals in 7 countries, randomized 3,608 hospitalized patients with bloodstream infections to receive either 7 or 14 days of antibiotics, with antibiotic selection, dosing, and route of administration at the discretion of the treating team. The primary outcome was 90-day mortality, with a 4% absolute non-inferiority margin.
Similar outcomes in both groups
A total of 1,814 patients received a 7-day course of antibiotics, and 1,794 received a 14-day course. At enrollment, 55% of patients were in the intensive care unit (ICU) and 45% on hospital wards. Infections were community-onset (75.4%), hospital-acquired (13.4%), or ICU-acquired (11.2%). Bacteremia sources were most commonly the urinary tract (42.2%), abdomen (18.8%), lung (13.0%), vascular catheters (6.3%), and skin or soft tissue (5.2%).
The primary outcome of 90-day mortality occurred in 14.5% of patients receiving 7 days of antibiotics and 16.1% of patients in the 14-day arm, for an absolute difference of –1.6% (95 % confidence interval [CI], –4.0% to 0.8%), demonstrating the non-inferiority of the 7-day treatment. The findings were generally consistent across secondary clinical outcomes and pre-specified patient, pathogen, and syndrome subgroups.
“These findings underscore the effectiveness of a shorter antibiotic regimen in patients with bloodstream infections, which is welcomed as we look to identify evidence-based prescribing guidelines for serious bacterial infections,” presenting author Nick Daneman, MD, clinician scientist in the Division of Infectious Diseases at Sunnybrook Health Sciences Centre and professor of Medicine at the University of Toronto, said in an IDWeek press release.